GLP-1 receptor agonists and dual/triple agonists are dominantly researched for obesity, but their effects on body composition and athletic performance have drawn growing interest in sport-science research. This article maps what the published literature actually shows about lean mass preservation, fat distribution, and performance endpoints in athletic research models.
The body composition question
Weight loss is not the same as fat loss. Any sustained caloric deficit reduces both fat mass and lean mass. The critical research question for athletes is: what fraction of the weight reduction comes from fat versus lean tissue?
DEXA scan data from the STEP and SURMOUNT trials shows that with semaglutide and tirzepatide, approximately 65-75% of weight loss is fat mass, with the remaining 25-35% lean mass — a ratio similar to traditional caloric restriction. The class does not preferentially spare lean tissue.
What that means in practical research terms
For populations where weight loss is the primary endpoint (obesity research), this composition split is acceptable. For athletic research populations with already-low body fat, the absolute lean mass loss is a meaningful variable. A 10% body weight loss in an athlete may translate to 2-3 kg lean tissue reduction — which has direct performance implications.
Resistance training as a confound
Research that combines GLP-1 agonist administration with structured resistance training shows attenuated lean mass loss. The SURMOUNT-1 trial did not control for exercise, but post-hoc analyses suggest participants who exercised consistently retained more lean mass — though the trial was not designed to test this.
Endurance research signals
GLP-1 agonists affect substrate utilisation by altering glycaemic regulation. In endurance research models:
- Improved insulin sensitivity may enhance glucose uptake during exercise
- Reduced caloric intake can compromise glycogen replenishment
- The gastrointestinal side effects (nausea, delayed gastric emptying) can impair tolerance of pre-workout nutrition
Net effect on endurance performance in sport-science research is mixed — and dependent on training phase, caloric availability, and individual response.
Strength and power research
Strength endpoints in GLP-1 research are limited. The available data shows:
- Absolute strength typically decreases proportional to lean mass loss
- Relative strength (per kg body weight) often improves due to greater body mass reduction
- Power output is affected by both lean mass and neural factors not directly addressed by GLP-1
The glucagon-arm angle (retatrutide)
The triple agonist retatrutide adds glucagon receptor activation, which raises energy expenditure. Theoretically this could allow greater fat loss at lower caloric deficits — preserving more lean mass for a given weight reduction. The published phase 2 data does not yet include DEXA scan body composition breakdowns, so this remains hypothesis pending more data.
Where the research is heading
- Combination protocols pairing GLP-1 agonists with myostatin inhibitors or growth-hormone secretagogues
- Athletic population studies in non-obese cohorts
- Substrate utilisation studies during prolonged endurance work
- Recovery and protein synthesis impact studies
Anti-doping consideration
GLP-1 receptor agonists are not currently on the WADA prohibited list. This may change if athletic-specific data accumulates. Sport-science researchers operating in regulated athletic populations should verify current status.
Research handling
Semaglutide, tirzepatide, and retatrutide are all supplied lyophilised. Reconstitution at 5–10 mg/mL in bacteriostatic water is standard. See our solvent guide for protocol detail.
Chempeptides supplies HPLC-verified GLP-1 class peptides for sport-science research — see the catalogue.
Research use only. This article summarises published research and is not medical, training, or competition advice.